Drugs / Vancomycin
Vancomycin
also known as
Vancomycin hydrochloride · VAN · Vancomycin HCl · Vancomycine · Firvanq · Firvanq kit · Novaplus · NSC-757377 · +24 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | TYZAVAN | — | 2021-05-28 – 2025-06-27 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCOMYCIN HYDROCHLORIDE | — | 2024-06-26 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCOCIN HYDROCHLORIDE | — | 2011-12-14 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER | — | 1998-01-08 | fda.gov ↗ |
| Approved | US (FDA) | VANCOCIN HYDROCHLORIDE | — | 1964-11-06 | fda.gov ↗ |
Trials 210 · started per year
today
US approved 1964
1
1
2
3
2
2
3
3
3
1
1
3
6
14
11
12
10
9
7
11
14
8
13
13
15
12
10
18
1963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT05849090 | Mar 2023 → Dec 2024 | infectious disease | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04246151 | Sep 2022 → Sep 2024 | Clostridium difficile colitis | Hamilton Health Sciences Corporation | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT05076955 | Mar 2021 → Aug 2022 | ulcer of lower limbs | University of Mississippi Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT01633762 | Apr 2012 → Apr 2013 | diabetes mellitus, obesity disorder, osteoporosis | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase 0 | NCT01878643 | Dec 2001 → Dec 2002 | primary bacterial infectious disease, respiratory failure, respiratory tract infectious disorder | Stony Brook University | Completed | No outcome recorded |
| Phase 118 trials · 1 met primary | ||||||
| Phase 1 | NCT07478848 | May 2026 → Jan 2029 expected | diffuse large B-cell lymphoma, large B-cell lymphoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06601257 | Apr 2025 → Apr 2026 | — | University of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT05777603 | Apr 2024 → Jun 2027 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT05539729 | Jan 2023 → Jun 2028 expected | multiple sclerosis | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT04816968 | Sep 2021 → Sep 2023 | bacterial infectious disease | Ospedale San Carlo Borromeo | Unknown | No outcome recorded |
| Phase 1 | NCT04673877 | Aug 2021 → Aug 2022 | infectious disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT04075526 | Oct 2019 → Jan 2024 | osteoarthritis | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT03546829 | Mar 2019 → Dec 2027 expected | non-small cell lung carcinoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT03685747 | Nov 2018 → Aug 2020 | infectious peritonitis | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT02663596 | Jan 2017 → Dec 2021 | kidney failure | Drexel University | Unknown | No outcome recorded |
| Phase 1 | NCT02618187 | Jan 2016 → Dec 2017 | ulcerative colitis | Seres Therapeutics, Inc. | Completed | Mixed |
| Phase 1 | NCT02464020 | Jul 2015 → May 2017 | inflammatory bowel disease, primary sclerosing cholangitis | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT02945241 | Apr 2014 → Jun 2015 | infectious disease with sepsis, methicillin-resistant staphylococcus aureus infectious disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01509339 | Jan 2012 → Dec 2021 | cystic fibrosis, methicillin-resistant staphylococcus aureus infectious disease | Case Western Reserve University | Withdrawn | No outcome recorded |
| Phase 1 | NCT01537666 | Nov 2011 → Mar 2012 | cystic fibrosis | Savara Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02137668 | Jul 2010 → May 2018 overdue | biliary atresia, primary sclerosing cholangitis | Sacramento Pediatric Gastroenterology | Recruiting | No outcome recorded |
| Phase 1 | NCT01085760 | Feb 2010 → Nov 2011 | primary sclerosing cholangitis | Mayo Clinic | Completed | Met primary |
| Phase 1 | NCT01322386 | May 2007 → Oct 2010 | biliary atresia, primary sclerosing cholangitis | Stanford University | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07605806 | May 2026 → May 2027 expected | hypersensitivity reaction disease | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06640491 | May 2025 → Dec 2030 expected | — | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06889701 | Apr 2025 → Aug 2026 overdue | periprosthetic joint infection | TenNor Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06651268 | Nov 2024 → Aug 2025 | — | Liaquat National Hospital & Medical College | Unknown | No outcome recorded |
| Phase 1/2 | NCT06126731 | Nov 2023 → Jun 2026 overdue | castration-resistant prostate carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03936998 | Jun 2019 → Nov 2023 overdue | food allergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03673956 | Sep 2018 → Feb 2021 | chronic rhinosinusitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 238 trials · 1 met primary · 5 missed | ||||||
| Phase 2 | NCT07646223 | Oct 2026 → Dec 2032 expected | primary sclerosing cholangitis, ulcerative colitis | Tampere University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07756255 | Aug 2026 → Aug 2028 expected | attention deficit-hyperactivity disorder | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07341282 | Jun 2026 → Dec 2027 expected | primary sclerosing cholangitis, ulcerative colitis | McMaster University | Recruiting | No outcome recorded |
| Phase 2 | NCT07463339 | May 2026 → Apr 2027 expected | — | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07300553 | Jan → Nov 2026 expected | Crohn disease, ulcerative colitis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT04993027 | Dec 2025 → Dec 2028 expected | periprosthetic joint infection | Alberta Hip and Knee Clinic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06747611 | Aug 2025 → Mar 2028 expected | alopecia areata, alopecia totalis, alopecia universalis | University of Minnesota | Recruiting | No outcome recorded |
| Phase 2 | NCT06503978 | Aug 2024 → Jul 2025 overdue | autism spectrum disorder, constipation disorder, diarrheal disease | Gut-Brain-Axis Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06321796 | Feb 2024 → Feb 2025 | Pitt-Hopkins syndrome | Gut-Brain-Axis Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05876182 | Jun 2023 → Jun 2026 overdue | inflammatory bowel disease, primary sclerosing cholangitis | University of Milano Bicocca | Recruiting | No outcome recorded |
| Phase 2 | NCT05695261 | Jun 2023 → Jan 2027 expected | anaphylaxis, food allergy | Rima Rachid | Recruiting | No outcome recorded |
| Phase 2 | NCT05697965 | Mar 2023 → May 2024 | periprosthetic joint infection | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT05607030 | Jan 2023 → May 2024 | periprosthetic joint infection | Osteal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05225558 | Apr 2022 → Feb 2024 | staphylococcal infection | LigaChem Biosciences, Inc. | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT05169229 | Apr 2022 → Dec 2028 expected | osteoarthritis, hip, periprosthetic joint infection | University Hospital, Linkoeping | Recruiting | No outcome recorded |
| Phase 2 | NCT04662632 | Nov 2021 → Mar 2023 | periprosthetic joint infection | Osteal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04025567 | Mar 2020 → Dec 2021 | hepatocellular carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04182633 | Nov 2019 → Feb 2025 overdue | autism spectrum disorder, constipation disorder, diarrheal disease | Arizona State University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04132427 | Sep 2019 → Mar 2022 | Pitt-Hopkins syndrome | Arizona State University | Completed | No outcome recorded |
| Phase 2 | NCT03785210 | Jun 2019 → Oct 2022 | colorectal cancer, hepatocellular carcinoma, malignant pancreatic neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03935828 | Jun 2019 → Dec 2020 | chronic rhinosinusitis, poisoning | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2 | NCT03721328 | Oct 2018 → Aug 2020 | periprosthetic joint infection | Osteal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03462459 | May 2018 → Jul 2023 | CADINS disease, Clostridium difficile colitis | University of Wisconsin, Madison | Completed | Missed primary |
| Phase 2 | NCT03408886 | Jan 2018 → Apr 2022 overdue | autism spectrum disorder, digestive system disorder | Arizona State University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02790996 | Feb 2017 → Apr 2020 | neonatal sepsis | PENTA Foundation | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02730962 | Jun 2016 → Jan 2018 | prediabetes syndrome | University of Minnesota | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02374853 | Mar 2015 → Apr 2019 | infectious disease | University of Alberta | Terminated | Missed primary |
| Phase 2 | NCT02037295 | Jan 2014 → Mar 2019 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Met primary |
| Phase 2 | NCT01925066 | Aug 2013 → Dec 2017 | methicillin-resistant staphylococcus aureus infectious disease, staphylococcal pneumonia | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02148601 | Jul 2013 → Nov 2014 | Clostridium difficile colitis | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 2 | NCT01746095 | Mar 2013 → Nov 2014 | cystic fibrosis | Savara Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01594827 | Oct 2012 → Dec 2017 | cystic fibrosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01427842 | Aug 2011 → Jul 2012 | — | The Canberra Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00945152 | Jul 2011 → Dec 2024 | bacterial infectious disease | Robert S Berman MD | Unknown | No outcome recorded |
| Phase 2 | NCT00695903 | Sep 2008 → Aug 2010 | bacterial endocarditis | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00426933 | Jan → Sep 2007 | — | Merck & Co., Inc. | Completed | Missed primary |
| Phase 2 | NCT00150852 | Sep 2004 → ? | skin infection | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase 2 | NCT00396578 | Aug 2003 → Sep 2004 | respiratory tract infectious disorder, tracheobronchitis | Stony Brook University | Completed | No outcome recorded |
| Phase 2/310 trials · 2 met primary | ||||||
| Phase 2/3 | NCT06748144 | May 2026 → Apr 2027 expected | — | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07221708 | Mar 2026 → Dec 2027 expected | Clostridium difficile colitis, Enterococcus faecalis infection | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06979609 | Nov 2025 → Oct 2028 expected | Clostridium difficile colitis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05625373 | Oct 2022 → Apr 2024 overdue | — | Women and Infants Hospital of Rhode Island | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04238923 | May 2020 → May 2021 | peripheral vascular disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 2/3 | NCT03710122 | Jan 2020 → Mar 2025 | primary sclerosing cholangitis | Elizabeth Carey | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT03506347 | Sep 2018 → Jan 2019 | arthropathy | Mayo Clinic | Completed | Met primary |
| Phase 2/3 | NCT03221023 | Sep 2017 → Sep 2021 | — | University of British Columbia | Unknown | No outcome recorded |
| Phase 2/3 | NCT02020031 | Dec 2013 → Jun 2015 | arthropathy | Mayo Clinic | Completed | Met primary |
| Phase 2/3 | NCT01798537 | Jun 2013 → Jul 2015 | bacterial infectious disease with sepsis | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 330 trials · 1 met primary · 4 missed | ||||||
| Phase 3 | NCT07659886 | Jun → Dec 2026 expected | — | Atlantic Health System | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07328971 | Apr 2026 → Jun 2030 expected | Clostridium difficile colitis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT07575009 | Apr 2026 → Dec 2028 expected | infectious disease | Tampere University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06126614 | May 2024 → Nov 2028 expected | periprosthetic joint infection | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT05766670 | Apr 2024 → Jan 2027 expected | osteomyelitis | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT07866157 | Dec 2023 → May 2026 | vertebral column disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05615844 | Nov 2023 → Mar 2027 expected | — | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 3 | NCT02590523 | Jan 2023 → Jan 2024 | cataract, endophthalmitis | Panhandle Eye Group, LLP | Suspended | No outcome recorded |
| Phase 3 | NCT05502380 | Sep 2022 → Dec 2024 overdue | bacterial infectious disease | Balgrist University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05320068 | Aug 2022 → Mar 2024 | Clostridium difficile colitis | Julia Orígüen | Completed | No outcome recorded |
| Phase 3 | NCT05084378 | Mar 2022 → Aug 2024 | periprosthetic joint infection | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT05256693 | Mar 2022 → Jun 2024 | Clostridium difficile colitis, disease related to hematopoietic stem cell transplant | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT04678154 | May 2021 → Sep 2026 overdue | — | Major Extremity Trauma Research Consortium | Recruiting | No outcome recorded |
| Phase 3 | NCT04731025 | Jan 2021 → Sep 2026 overdue | breast disorder, poisoning, prosthesis-related infectious disease | Mikkel Herly | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05959603 | May 2020 → Dec 2025 overdue | infectious disease | Rabin Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT03303677 | Apr → Nov 2018 | chronic rhinosinusitis | University of Florida | Withdrawn | No outcome recorded |
| Phase 3 | NCT03181932 | Sep 2017 → Jul 2020 | cystic fibrosis, methicillin-resistant staphylococcus aureus infectious disease | Savara Inc. | Completed | Missed primary |
| Phase 3 | NCT02774382 | May 2017 → Dec 2018 | Clostridium difficile colitis | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02432807 | May 2015 → May 2018 | bacterial conjunctivitis | Kurobe LLC | Completed | Missed primary |
| Phase 3 | NCT02284126 | Oct 2014 → Nov 2019 | infectious disease | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT02227446 | Oct 2014 → Jun 2018 | — | Major Extremity Trauma Research Consortium | Completed | Missed primary |
| Phase 3 | NCT01983683 | Dec 2013 → Mar 2017 | Clostridium difficile colitis | Actelion | Completed | Missed primary |
| Phase 3 | NCT01792804 | Dec 2013 → Mar 2020 | staphylococcus aureus infection | Heinrich-Heine University, Duesseldorf | Completed | Met primary |
| Phase 3 | NCT01802073 | Jan 2012 → Aug 2015 | primary sclerosing cholangitis | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT00108433 | Sep 2005 → Sep 2006 | gram-positive bacterial infections | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00138112 | Nov 2003 → Nov 2005 | bacterial infectious disease with sepsis, hematopoietic and lymphoid cell neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00228410 | Nov 2002 → Dec 2003 | skin infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00037050 | Apr 2002 → Jul 2005 | gram-positive bacterial infections | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00035425 | Nov 2001 → Nov 2002 | neutropenia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00003805 | Nov 1997 → Jun 2000 | bone marrow disorder, cancer of unknown primary site, childhood malignant neoplasm, infectious disease +3 | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 461 trials · 3 met primary · 1 missed | ||||||
| Phase 4 | NCT07633418 | Jun 2026 → Apr 2027 expected | — | University of California, San Diego | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07547826 | May 2026 → May 2027 expected | bacterial infectious disease, hydrocephalus, prosthesis-related infectious disease | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06567808 | Mar 2026 → Apr 2028 expected | skin infection | Hamilton Health Sciences Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07376889 | Feb 2026 → Jan 2029 expected | staphylococcus aureus infection | Intermountain Health Care, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT07220967 | Oct 2025 → Oct 2027 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07338773 | Aug 2025 → Jun 2026 | diabetic peripheral angiopathy | Başakşehir Çam & Sakura City Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06504992 | Nov 2024 → Sep 2028 expected | disease of bone structure, skin infection | University of Manitoba | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07282782 | Jun 2024 → Dec 2026 expected | — | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 4 | NCT06148025 | Nov 2023 → Oct 2027 expected | — | South Australian Health and Medical Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT05831774 | Jun 2023 → Jul 2024 overdue | arthropathy | The Methodist Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05705843 | Jan 2023 → Jan 2024 | infectious disease | The Methodist Hospital Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT05276687 | Sep 2022 → Mar 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05394298 | Jul 2022 → Jul 2024 | Enterococcus infectious disease | Andalusian Public Foundation for Health Research in Seville | Unknown | No outcome recorded |
| Phase 4 | NCT05156437 | Mar 2022 → Oct 2024 | endocarditis | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05137119 | Feb 2022 → Dec 2028 expected | staphylococcus aureus infection | University of Melbourne | Recruiting | Mixed |
| Phase 4 | NCT05079620 | Nov 2021 → Apr 2024 | aspiration pneumonia, aspiration pneumonitis | UConn Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04948463 | Nov 2021 → Dec 2025 | neutropenia | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT05535075 | Nov 2021 → Nov 2023 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT04872400 | Jun 2021 → Sep 2023 | disease of bone structure, skin infection | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT04856878 | Jun 2021 → Jun 2024 | — | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT06161870 | Jan 2021 → Dec 2024 overdue | primary bacterial infectious disease | Central South University | Recruiting | No outcome recorded |
| Phase 4 | NCT04666948 | Dec 2020 → Dec 2023 | — | University Hospital, Ghent | Completed | Met primary |
| Phase 4 | NCT03765567 | Oct 2020 → Sep 2027 expected | — | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 4 | NCT04500275 | Jul 2020 → Mar 2025 | — | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03713528 | Jan 2020 → Jan 2027 expected | periprosthetic joint infection | OrthoCarolina Research Institute, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04042233 | Dec 2019 → May 2022 | periprosthetic joint infection | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT05535725 | Oct 2019 → Oct 2021 | — | Clinique Ortos | Completed | No outcome recorded |
| Phase 4 | NCT04088305 | Oct 2019 → May 2022 | staphylococcal pneumonia | Peking University Third Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04000555 | Sep 2019 → Jun 2022 | Clostridium difficile colitis | University of South Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04044703 | Aug 2019 → Dec 2020 | bacterial infectious disease, infectious disease with sepsis | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03928522 | Jan → Sep 2019 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03308253 | Jul 2018 → Jun 2019 | — | McMaster University | Unknown | No outcome recorded |
| Phase 4 | NCT03466502 | Mar 2018 → Feb 2022 | Clostridium infectious disease | University of Nevada, Reno | Completed | No outcome recorded |
| Phase 4 | NCT03200093 | Jun 2017 → Apr 2021 | Clostridium difficile colitis | Rochester General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03051698 | Nov 2016 → Oct 2019 | asthma | T. van der Poll | Terminated | No outcome recorded |
| Phase 4 | NCT02951702 | Nov 2016 → May 2017 | Clostridium difficile colitis | St. Luke's Hospital, Chesterfield, Missouri | Completed | No outcome recorded |
| Phase 4 | NCT03412500 | Oct 2016 → Sep 2018 | methicillin-resistant staphylococcus aureus infectious disease | Pinyo Rattanaumpawan | Unknown | No outcome recorded |
| Phase 4 | NCT03585426 | Mar 2016 → Dec 2018 | — | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02667418 | Feb 2016 → Aug 2024 | Clostridium infectious disease | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02605213 | Sep 2015 → Feb 2016 | primary sclerosing cholangitis | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT02631408 | Aug 2015 → Mar 2019 | skeletal system disorder | Orthopedic Hospital Vienna Speising | Completed | No outcome recorded |
| Phase 4 | NCT02478710 | Jun 2015 → Feb 2017 | — | Wright State University | Terminated | No outcome recorded |
| Phase 4 | NCT02400112 | Mar 2015 → Oct 2018 | — | University of Tennessee | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02254967 | Nov 2014 → Mar 2016 | Clostridium difficile colitis | Astellas Pharma Europe Ltd. | Completed | Met primary |
| Phase 4 | NCT02237859 | Aug 2014 → Aug 2016 | Clostridium difficile colitis | Corewell Health West | Unknown | No outcome recorded |
| Phase 4 | NCT02096536 | Apr 2014 → Jan 2025 overdue | — | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 4 | NCT02926846 | Mar 2014 → Nov 2017 | kidney failure, peritonitis | Alice Ho Miu Ling Nethersole Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02443064 | Jan 2014 → Jan 2016 | bacterial infectious disease with sepsis, endocarditis, methicillin-resistant staphylococcus aureus infectious disease | Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT01786161 | Sep 2013 → Jun 2016 | methicillin-resistant staphylococcus aureus infectious disease | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01952834 | Jun 2013 → Mar 2015 | coronary artery disorder | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 4 | NCT03453684 | Dec 2012 → Jun 2013 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT01628666 | Dec 2012 → Sep 2017 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01820026 | Dec 2012 → May 2015 | cirrhosis of liver | University of Roma La Sapienza | Unknown | Met primary |
| Phase 4 | NCT01626560 | Jul 2012 → Mar 2015 | cellulitis | Hospital Universitario Evangelico de Curitiba | Completed | No outcome recorded |
| Phase 4 | NCT01592032 | May 2012 → Jan 2015 | bacterial infectious disease, prosthesis-related infectious disease | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 4 | NCT01458223 | Oct 2011 → Aug 2018 | — | The London Spine Centre | Completed | No outcome recorded |
| Phase 4 | NCT00445094 | Nov 2006 → Jan 2007 | pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00295178 | Feb → Aug 2006 | cellulitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00281281 | Dec 2005 → Apr 2007 | — | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00087490 | Oct 2004 → Jul 2007 | methicillin-resistant staphylococcus aureus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00572559 | Nov 2002 → Jan 2005 | — | Pfizer | Completed | Missed primary |
| Phase not applicable39 trials · 2 met primary · 3 missed | ||||||
| — | NCT07826351 | Sep 2026 → Jan 2027 expected | bacterial meningitis | yilong Wang | Not yet recruiting | No outcome recorded |
| — | NCT07283068 | Jun 2026 → Feb 2030 expected | — | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| — | NCT07120490 | Oct 2025 → Mar 2027 expected | Clostridium difficile colitis | Medical University of Warsaw | Not yet recruiting | No outcome recorded |
| — | NCT06702345 | Mar 2025 → Jul 2026 overdue | Clostridium difficile colitis | Leiden University Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT06373640 | Nov 2024 → Mar 2027 expected | subarachnoid hemorrhage | University Hospital Southampton NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| — | NCT06543940 | Sep 2024 → Aug 2025 overdue | acute kidney injury | Mahidol University | Recruiting | No outcome recorded |
| — | NCT06189885 | Aug 2024 → Jul 2026 overdue | periprosthetic joint infection | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06166381 | Jan → Dec 2024 overdue | bacterial infectious disease | University of Duhok | Recruiting | No outcome recorded |
| — | NCT05964114 | Oct 2023 → Oct 2025 | — | Erasmus Medical Center | Unknown | No outcome recorded |
| — | NCT04793152 | Mar 2023 → Jul 2029 expected | methicillin-resistant staphylococcus aureus infectious disease | Anthony Bai | Recruiting | No outcome recorded |
| — | NCT05363462 | Jan 2022 → Dec 2023 | — | Autonomous University of Nuevo León | Completed | No outcome recorded |
| — | NCT04839653 | May 2021 → Apr 2022 | acute respiratory distress syndrome, bacterial infectious disease, infectious disease with sepsis, pneumonia | MEDSI Clinical Hospital 1, ICU | Unknown | No outcome recorded |
| — | NCT03688659 | Jan 2019 → Jan 2021 | infective endocarditis | Assiut University | Unknown | No outcome recorded |
| — | NCT03809260 | Dec 2018 → Feb 2019 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03883022 | Sep 2018 → Sep 2027 expected | spinal stenosis, spondylolisthesis | Taipei Veterans General Hospital, Taiwan | Recruiting | Met primary |
| — | NCT03157388 | Jun 2017 → Jun 2018 | alcoholic hepatitis | University of Aarhus | Completed | No outcome recorded |
| — | NCT03046901 | Dec 2016 → Feb 2019 | primary sclerosing cholangitis | Ochsner Health System | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02764359 | Aug 2016 → Apr 2024 | infectious disease with sepsis, obesity disorder | CAMC Health System | Completed | No outcome recorded |
| — | NCT02154061 | Apr 2015 → May 2017 | influenza | Emory University | Completed | No outcome recorded |
| — | NCT02285140 | Apr 2015 → Mar 2025 | — | Hamilton Health Sciences Corporation | Terminated | No outcome recorded Stop: Business |
| — | NCT02411331 | Mar 2015 → Jan 2017 | staphylococcal infection | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| — | NCT02127749 | Jun 2014 → Dec 2015 | — | Academic Medical Center - University of Amsterdam | Completed | Missed primary |
| — | NCT02216227 | Apr 2014 → Feb 2021 | — | VA Office of Research and Development | Completed | Missed primary |
| — | NCT02033408 | Jan 2014 → Dec 2018 | Crohn's colitis, ulcerative colitis | Shaare Zedek Medical Center | Completed | Met primary |
| — | NCT02413034 | Nov 2013 → Dec 2014 | periprosthetic joint infection | Parc de Salut Mar | Completed | No outcome recorded |
| — | NCT02340182 | Mar → Sep 2013 | infectious disease with sepsis | W.J. Wiersinga, MD, PhD | Completed | No outcome recorded |
| — | NCT01720940 | Oct 2012 → Sep 2015 | — | National University Hospital, Singapore | Unknown | No outcome recorded |
| — | NCT02299882 | Aug 2012 → Aug 2015 | vertebral column disorder | Corewell Health West | Unknown | No outcome recorded |
| — | NCT01566422 | Jun 2012 → Dec 2014 | — | Vanderbilt University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01623817 | Jun → Dec 2012 | infectious disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT02241421 | Apr 2012 → Oct 2014 | obesity disorder | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT01346059 | Apr 2011 → Feb 2012 | colitis | Corewell Health East | Terminated | No outcome recorded |
| — | NCT01290237 | Feb 2011 → Feb 2012 | infectious disease | Boston Children's Hospital | Terminated | Missed primary Stop: Enrollment |
| — | NCT01157533 | Jun 2010 → Jan 2012 | infectious disease | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00915967 | May 2009 → Dec 2014 | — | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00596167 | Sep 2007 → Apr 2009 | end stage renal failure, infectious disease | Indiana University | Completed | No outcome recorded |
| — | NCT00355602 | Jul 2006 → Dec 2008 | ulcerative colitis | University of Dundee | Completed | No outcome recorded |
| — | NCT00612469 | Oct 2005 → Jul 2006 | dental caries | Federal University of Ceará | Completed | No outcome recorded |
| — | NCT00175370 | Sep 2000 → Dec 2007 | staphylococcal infection | University of British Columbia | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT06383611 | — | periprosthetic joint infection | Osteal Therapeutics, Inc. | Temporarily not available | No outcome recorded |
| — | NCT04878718 | — | autism | ProgenaBiome | No longer available | No outcome recorded |
| Comparator or background therapy237 trials | ||||||
| Phase 0 | NCT05829109 Background | Sep 2024 → Dec 2026 expected | pouchitis | Maia Kayal | Recruiting | No outcome recorded |
| Phase 0 | NCT06197308 Background | Mar 2024 → Mar 2027 expected | primary sclerosing cholangitis | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT04968951 Comparator | Nov 2021 → Aug 2022 | ulcerative colitis | Ari M Grinspan | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT06967376 Comparator | May 2018 → Nov 2021 | keratitis | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Show all 237 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Acurx Pharmaceuticals Inc. | Results Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures acurxpharma.com ↗
All vancomycin-resistant Enterococcus (VRE) strains demonstrated high-level resistance to VAN (MIC >128 μg/mL), whereas IBZ and FDX exhibited equivalent lower susceptibility thresholds (MIC range: 2–16 μg/mL). |
| 2024-01-29 | Acurx Pharmaceuticals Inc. | Results Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients acurxpharma.com ↗
In the vancomycin control arm of the trial, 7 of 7 patients experienced no recurrence of infection. |
| 2024-01-17 | Acurx Pharmaceuticals Inc. | Results Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients acurxpharma.com ↗
Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin which had eradication of C. difficile in 10 of 14 treated patients (71%). |
| 2023-12-11 | Acurx Pharmaceuticals Inc. | Results Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure acurxpharma.com ↗
2 of 14 patients treated with standard of care, oral vancomycin, experienced recurrent infection within one month after EOT for a SCC of 86% |
| 2023-10-02 | Acurx Pharmaceuticals Inc. | Results Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection acurxpharma.com ↗
Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as expected |
| 2015-02-02 | Lupin Limited | Regulatory Lupin Receives FDA Approval for Generic Vancocin® Capsules lupin.com ↗ |
All press releases naming this drug 10 releases
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 449 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vancomycin | “The investigators want to compare whether Methicillin-resistant Staphylococcus Aureaus (MRSA) antibiotic prophylaxis with Cefazolin plus Daptomycin is superior to Cefazolin...” NCT01612052 ↗442“Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or...” NCT01728376 ↗ “Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin,...” NCT07072923 ↗ “In the intervention arm, participants with airway microbiome positive for VAP pathogens will receive inhaled tobramycin, participants with airway S. aureus will receive inhaled...” NCT07463339 ↗ “Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through...” NCT00596167 ↗ “This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin,...” NCT02168816 ↗ “Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below: Cefazolin 10mg/mL...” NCT05971537 ↗ “'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin;...” NCT00634166 ↗ “Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the...” NCT03176134 ↗ “systemic bioavailability of vancomycin in healthy volunteers following single dose pulmonary administration of 16 mg, 32 mg, and 80 mg doses of AeroVanc in comparison with a...” NCT01537666 ↗ “Initial antimicrobial therapy for both groups consisted of fortified vancomycin eye drops 50 mg/ml, fortified ceftazidime eye drops 50 mg/ml hourly, and the antifungal agent...” NCT06967376 ↗ |
| Known as | Firvanq | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Firvanq kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Novaplus | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | NSC-757377 | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Oral vancomycin | “Oral vancomycin is an antibiotic that is commonly used to treat CDI.” NCT04241744 ↗ |
| Known as | PremierPro Rx | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Pulvules | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | U-VANCO | “with U-VANCO (vancomycin hydrochloride)” NCT03883022 ↗ |
| Known as | VAN | “linezolid (LZD) therapy with that of vancomycin (VAN) therapy” PMID 18719064 ↗ Aug 20081“Vancomycin (VAN) treatment” NCT07659886 ↗ |
| Known as | Vancocin | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Vancocin (vancomycin) | “Vancocin (vancomycin)” NCT00596167 ↗ |
| Known as | Vancocin HCl | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Vancocin hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancocin i.v. | “Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially)...” NCT04017468 ↗ |
| Known as | Vancocin matrigel | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancogel(R) | “Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)” NCT00945152 ↗ |
| Known as | Vancoled | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗ |
| Known as | Vancomicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancomycin "Hospira" | “vancomycin 500 mg (Vancomycin "Hospira"), powder for concentrate” NCT03157388 ↗ |
| Known as | Vancomycin (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | vancomycin (China Chemical & Pharmaceutical Co., Ltd. (CCPC / Taiwan)) | “vancomycin® (China Chemical & Pharmaceutical Co., Ltd. (CCPC / Taiwan))” NCT04500275 ↗ |
| Known as | Vancomycin (Vancocin) | “Vancomycin (Vancocin)” NCT00818766 ↗ |
| Known as | Vancomycin HCl | “Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)” NCT01731236 ↗1“Drug: Vancomycin HCL” NCT01623817 ↗ |
| Known as | Vancomycin HCL: Brand name Vancocin | “Vancomycin HCL: Brand name Vancocin” NCT01619982 ↗ |
| Known as | Vancomycin hydrochloride | “Protocol for Expanded Access to Cyclic Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Exchange Arthroplasty for Periprosthetic Joint...” NCT06383611 ↗8“Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight” NCT01619982 ↗ “Vancomycin hydrochloride dry powder for inhalation” NCT01537666 ↗ “with U-VANCO (vancomycin hydrochloride)” NCT03883022 ↗ “Drug: Vancomycin Hydrochloride” NCT04500275 ↗ |
| Known as | Vancomycin monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancomycin-Vanco-Teva | “Vancomycin-Vanco-Teva®” NCT02033408 ↗ |
| Known as | vancomycin: vancomicina sala 500 mg vial. | “vancomycin: vancomicina sala 500 mg vial.” NCT01592032 ↗ |
| Known as | Vancomycine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02411331 ↗ |
| Known as | Vancor | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Known as | Vancozin 250 mg capsule | “Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)” NCT03403972 ↗ |
| Known as | Vanoled | ChEMBL registry synonym — accepted as the source's own label CHEMBL262777 ↗ |
| Action | Inhibit | “inhibits bacterial growth by hindering the synthesis of cell wall in bacteria” NCT02443064 ↗ |
| Modality | Other / unclassified | “Vancomycin is a glycopeptide antibiotic” NCT01509339 ↗ |
| Route | Intravenous | “Vancomycin IV is administered over at least 1 hour twice daily.” NCT00003805 ↗ |